Zealand Pharma A/S (OTCMKTS:ZLDPF) Reaches New 1-Year Low – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $74.26 and last traded at $74.26, with a volume of 313 shares traded. The stock had previously closed at $77.00.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ZLDPF shares. William Blair raised Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 7th. Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, January 21st.

Zealand Pharma A/S Stock Performance

The stock has a market capitalization of $7.02 billion, a price-to-earnings ratio of -41.91 and a beta of 0.92. The company has a debt-to-equity ratio of 0.03, a quick ratio of 35.49 and a current ratio of 35.49. The stock has a fifty day simple moving average of $97.68 and a two-hundred day simple moving average of $109.51.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.19. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%. The company had revenue of $1.30 million during the quarter, compared to analyst estimates of $28.11 million. Analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.